Anesthesia · Opioid
The FDA's review of Fresenius Kabi's supplemental application for Remifentanil Hydrochloride is significant as it may alter competitive dynamics in the anesthetic market. Companies should prepare for potential shifts in market share and adjust their strategies accordingly.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/9/2026, 6:32:15 PM
Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's review of Fresenius Kabi's supplemental application for Remifentanil Hydrochloride is significant as it may alter competitive dynamics in the anesthetic market. Companies should prepare for potential shifts in market share and adjust their strategies accordingly. Regulatory context from FDA (FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (4 high-relevance).
Portfolio teams should assess the impact of this submission on market dynamics and consider strategic positioning against competitors in the anesthetic space. The strongest clinical anchor is The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery (ClinicalTrials.gov), sub-indication match (pain). In pain, 1 regulatory and 1 competitive items passed relevance filtering for Remifentanil Hydrochloride.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This submission indicates Fresenius Kabi's intent to expand its portfolio in the anesthetic market, potentially increasing competition with existing opioid products.
Regulatory risk is concentrated around FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL) (FDA). Entity match (remifentanil hydrochloride); Regulatory pathway relevance (nda). The standard review process indicates a moderate timeline for approval, which could affect market readiness and compliance strategies for competitors.
FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (remifentanil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — NILOTINIB HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View sourceThe Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View sourceOpioid Rapid Response System: Naloxone Training in Communities
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View sourceMirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View sourceUltrasound-Guided Intermediate Cervical Plexus Block for Postoperative Analgesia in Vagus Nerve Stimulation Surgery
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View sourceTranscranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View sourceVertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's review of Fresenius Kabi's supplemental application for Remifentanil Hydrochloride is significant as it may alter competitive dynamics in the anesthetic market. Companies should prepare for potential shifts in market share and adjust their strategies accordingly.
If approved, this product could enhance Fresenius Kabi's portfolio, potentially impacting the market share of existing opioid anesthetics and altering competitive positioning.
The standard review process indicates a moderate timeline for approval, which could affect market readiness and compliance strategies for competitors.
Monitor the FDA's review timeline and any subsequent approval announcements for Remifentanil Hydrochloride.
Track for follow-up milestones; no immediate action required.